Clinical trials: Immunoglobulin
Breast Cancer, Ovarian Cancer
FPA150 in Patients With Advanced Solid Tumors
This is a multi-center study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of FPA150, an anti-B7H4 antibody alone or in combination with pembrolizumab an anti-PD1…
- Conditions
- Breast Cancer, Ovarian Cancer, Endometrial Cancer, Advanced Solid Tumors
- Trial name
- FPA150-001 (NCT03514121)
- Testing
- FPA150, Pembrolizumab
- Where
- 18 sites in United States, South Korea
- Volunteers
- 95 people
- Sponsor
- Five Prime Therapeutics, Inc.
Systemic Lupus Erythematosus
A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)
The purpose of this study is to assess the impact of belimumab on immune response to pneumococcal vaccine in subjects with Systemic Lupus Erythematosus (SLE).
- Trial name
- NCT01597492
- Testing
- Belimumab plus Early Vaccination, Belimumab plus Late Vaccination
- Where
- 15 sites in United States
- Volunteers
- 79 people
- Sponsor
- Human Genome Sciences Inc., a GSK Company
Chronic Hepatitis b, Anti-PD-1 Antibody
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)
Hepatitis B virus (HBV) infection is a major public health threat in China. At present, a functional cure, also known as clinical cure or sustained Hepatitis B surface antigen (HBsAg) loss, is recommended as the ideal endpoint of…
- Trial name
- NCT05769816
- Testing
- Anti-PD-1 antibody, NAs
- Where
- China
- Volunteers
- 120 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Nasopharyngeal Carcinoma
A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)
A phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with recurrent or metastatic nasopharyngeal carcinoma who had failed at least two lines of platinum-based…
- Trial name
- NCT06118333
- Testing
- BL-B01D1, capecitabine, gemcitabine
- Where
- China
- Volunteers
- 386 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Lymphoma
Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00072449
- Testing
- rituximab
- Where
- 9 sites in United States
- Volunteers
- 12 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Medullary Thyroid Carcinoma
ImmunoTEP for Patients With Medullary Thyroid Carcinoma.
The aim of this study is to optimize pretargeting parameters using pharmacokinetic and imaging data for immuno-PET using anti-CEA x anti-HSG TF2 BsMAb and 150 MBq of 68Ga-IMP-288 peptide in MTC patients with abnormal Ct serum…
- Trial name
- iTEP-CMT (NCT01730638)
- Testing
- • TF2 and 68 Ga-IMP-288
- Where
- 3 sites in France
- Volunteers
- 25 people
- Sponsor
- Nantes University Hospital
Covid19, Pneumonia
Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment
Pneumonia caused by coronavirus infection COVID-19 is characterized by a combination of several dangerous factors that consistently worsen the patient's condition: viral lung damage early in the disease; a sharp increase in…
- Trial name
- NCT04500067
- Testing
- IVIG
- Where
- 9 sites in Ukraine
- Volunteers
- 76 people
- Sponsor
- Biopharma Plasma LLC
Primary Immunodeficiency Diseases (PID)
Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN)
This study will provide insights on the infusion parameters, dosing, and experience of participants transitioning to CUVITRU in a real-world setting.
- Trial name
- NCT03716700
- Testing
- CUVITRU
- Where
- 3 sites in Canada
- Volunteers
- 126 people
- Sponsor
- Baxalta now part of Shire
Immunology
ABO Blood Group Antibody Elimination by a Combination of Semiselective Immunoadsorption Therapy and Membrane Filtration
Recipient desensitization protocols were shown to enable successful living donor kidney transplantation across major ABO blood group barriers.
- Trial name
- NCT01698736
- Testing
- Membrane filtration, Semiselective IA
- Where
- Austria
- Volunteers
- 14 people
- Sponsor
- Medical University of Vienna
Advanced Solid Tumor
Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors
This is a multi-center phase II clinical trial to evaluate the anti-tumor activity and safety of HX009 in subjects with advanced solid tumors.
- Trial name
- NCT04886271
- Testing
- HX009
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Hangzhou Hanx Biopharmaceuticals, Ltd.
Rubella, Mumps
Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age
The purpose of this study is to compare two measles, mumps and rubella conjugate vaccines (manufactured by GSK and Merck and Company ) in terms of the immune response elicited and safety with a six month follow-up after first…
- Conditions
- Rubella, Mumps, Measles, Measles-Mumps-Rubella Vaccine
- Trial name
- NCT00861744
- Testing
- GSK Biological's investigational vaccine 209762, M-M-R® II (Merck and Co), Varivax®
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 1,259 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients
Severe and critically ill patients will be enrolled in the study (50 patients) after duly filled consent forms. Recipients shall be divided in to 5 groups with 10 patients per group to compare clinical efficacy and safety of…
- Trial name
- NCT04521309
- Testing
- SARS-CoV-2 antibody based IVIG therapy
- Where
- Pakistan
- Volunteers
- 50 people
- Sponsor
- Dow University of Health Sciences
Gastric Cancer
Safety and Efficacy of NK510 to Treat Gastric Cancer
This study will evaluate the safety and efficacy of NK510 in the treatment of relapsed and refractory advanced gastric cancer.NK510 will be administered in combination with PD-1 blockade or monoclonal anti-HER2 antibody.
- Trial name
- NCT06098898
- Testing
- NK510, Tislelizumab，atezolizumab or Trastuzumab
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Base Therapeutics (Shanghai) Co., Ltd.
Metastatic Breast Cancer, Lung Metastases
Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions
This study will test the investigational antibody, MEDI6469 (anti-OX40), in combination with stereotactic body radiation in breast cancer patients that have liver or lung metastases and have received systemic therapy and have…
- Conditions
- Metastatic Breast Cancer, Lung Metastases, Liver Metastases
- Trial name
- OX40 Breast (NCT01862900)
- Testing
- MEDI6469
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Providence Health & Services
Non-small Cell Lung Cancer
A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC)
The primary purpose of this study is to examine the safety of volociximab (V) in combination with a standard treatment of carboplatin (C), paclitaxel (P), and bevacizumab (B) in subjects previously untreated with chemotherapy for…
- Trial name
- NCT00666692
- Testing
- M200 (Volociximab), Carboplatin, Paclitaxel, Bevacizumab
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Abbott
Nasopharyngeal Carcinoma
Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma
This study is a randomized, placebo-controlled, double-blind, multicenter phase III clinical study. Target population is patients with recurrent/metastatic nasopharyngeal carcinoma who had not received systemic chemotherapy.
- Trial name
- NCT03707509
- Testing
- Camrelizumab, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 263 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Anemia, Hemolytic, Autoimmune
Prednisolone +/- Addition of Anti-CD20 Antibody, Rituximab, in Patients With Immune Hemolytic Anemia
The conventional treatment in warm-antibody dependent autoimmune haemolytic anaemia (AIHA) is high-dose glucocorticoid, but in more than half of the patients, haemolytic activity will recur after end of treatment or during the…
- Trial name
- NCT01134432
- Testing
- prednisolone + mabthera, Prednisolone
- Where
- 11 sites in Denmark
- Volunteers
- 65 people
- Sponsor
- Copenhagen University Hospital at Herlev
Pertussis, Vaccination
Maternal Antibody in Milk After Vaccination
Single-centre observational pilot study exploring pertussis specific antibody concentration in the breastmilk of women vaccinated against pertussis in pregnancy at different gestational ages.
- Conditions
- Pertussis, Vaccination, Pregnancy, Breastmilk
- Trial name
- MAMA (NCT03982732)
- Testing
- Boostrix-IPV
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- St George's, University of London
Malaria
Trial to Evaluate CIS43LS in Healthy Adults
Background: People get malaria when they are bitten by an infected mosquito. Malaria can be serious and sometimes deadly. Although there are medicines to treat malaria, there is no vaccine that fully prevents infection.
- Trial name
- NCT04206332
- Testing
- VRC-MALMAB0100-00-AB, Plasmodium falciparum (P. falciparum) sporozoite challenge
- Where
- 2 sites in United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Esophageal Squamous Cell Carcinoma Abdominal Stage 0
PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC
This trial is a prospective, multicenter, randomized controlled trial. The sample size was 380. Patients with advanced or metastatic esophageal squamous cell carcinoma will be randomized to receive PD1 antibody combined with…
- Trial name
- Escape (NCT05737563)
- Testing
- PD-1 Inhibitors, Irinotecan, Capecitabine tablets
- Where
- China
- Volunteers
- 380 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.